Market Intelligence, Clinical Progress, and High-Purity Reagents for Selective mTORC2 Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SIN1/MAPKAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAPKAP1 (SIN1) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Designed for PPI and binding assays. |
View MAPKAP1 Products |
| Gene Delivery | MAPKAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to monitor downstream phosphorylation. |
View MAPKAP1 Products |
| Benchmark Ab | Anti-MAPKAP1 Recombinant Antibody Recombinant positive control for Western Blot and Immunoprecipitation. |
View MAPKAP1 Products |
| Validator | MAPKAP1 siRNA Set For knockdown verification and target validation assays. |
View MAPKAP1 Products |
| Related Target A | RICTOR Essential scaffold subunit of mTORC2; key partner for complex assembly and selectivity assays. |
View RICTOR Products |
| Related Target B | mTOR Catalytic subunit of both mTORC1 and mTORC2; critical for counter-screening and dual-inhibitor profiling. |
View mTOR Products |
| Related Target C | AKT1 Primary downstream substrate of mTORC2 (phosphorylated at Ser473); essential for functional readout. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disrupting Protein-Protein Interactions (PPI) | Sequence-verified SIN1/MAPKAP1 and RICTOR recombinant proteins with high purity (>95%) for robust ELISA/HTRF screening. |
| Subfamily and Complex Selectivity (mTORC1 vs. mTORC2) | Purified target panel components (mTOR, RICTOR, RAPTOR) strictly verified by SDS-PAGE and mass spectrometry. |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for target knockdown and specificity verification in cell-based assays. |
Live SIN1/MAPKAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for selective mTOR inhibition is shifting from non-selective dual mTORC1/mTORC2 inhibitors to highly selective mTORC2 inhibitors. SIN1 (encoded by the MAPKAP1 gene) is an indispensable subunit of mTORC2, playing a critical role in complex assembly, membrane localization via its PH domain, and substrate recruitment (such as AKT phosphorylation at Ser473). Because dual mTORC1/2 inhibition often triggers severe metabolic side effects and immunosuppression due to mTORC1 disruption, targeting the SIN1-mTORC2 interface represents a highly promising therapeutic strategy.
As next-generation therapies enter preclinical and early clinical evaluations, major pharmaceutical developers are focusing on disrupting the SIN1-mTOR interaction or utilizing PROTACs to selectively degrade mTORC2 components, bypassing the toxicities associated with traditional pan-mTOR inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Spin-offs, Biotech | Breast Cancer, Glioblastoma, Colorectal Cancer | In vitro binding and disruption assays (Requires high-purity SIN1/MAPKAP1 and RICTOR proteins) |
| PROTAC (Degrader) | Arvinas, Kymera Therapeutics (Discovery) | Hematological Malignancies, Solid Tumors | Protein degradation kinetics (Requires Lentivirus for stable cell line construction and target validation) |
| RNA Therapeutics (siRNA) | Alnylam, Arrowhead (Discovery) | Metabolic Disorders, Oncology | In vitro target knockdown validation (Requires sequence-verified siRNA and quantitative RT-PCR/Western controls) |